Lymfactin® aims to become the first drug for treating secondary lymphedema

By Herantis Pharma

Lymfactin® is currently in a randomized, double-blind, placebo-controlled, multi center, Phase 2 clinical study in Finland and Sweden in patients suffering from breast cancer associated secondary lymphedema.

Read more here.

Read more about Lymfactin here.

Recommended Articles

Translate »
error: Content is Protected